Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History

MedMira Inc V.MIR

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  MMIRF

MedMira Inc is a biotechnology company. It is engaged in the business of research and development and manufacturing of rapid diagnostics and technology.
Price: $0.06 | Change: $-0.01 | %Change: -14.29%
Volume: 3,216 | Day High/Low: 0.06/0.06 | 52 Week High/Low: 0.14/0.045

Snapshot

Last Traded: July 29, 2014 11:37 Transaction Volume: 3,216
Open: $0.06 Previous Close: $0.07
Bid: $0.06 Ask: $0.065
Bid Size: 40,000 Ask Size: 64,000
Market Cap: $30.9m Shares Out: 514.4m
PE Ratio: N/A Dividend Yield: N/A
Scale: 1d 5d 3m 6m 1y 2y 5y
Type: Line Area OHLC

Advanced Charts

Latest News

MedMira Expands Multiplo Product Range with Three New Rapid Vertical Flow Tests

Canada NewsWire   13 days ago
0 stars

MedMira (V.MIR) ramps up Chinese market share with additional tender sales

MedMira's (V.MIR) top-ranking rapid HIV-test is taking China by storm and steadily gaining critical market share

Stockhouse Editorial   July 14, 2014
0 stars

Top Ranking MedMira Rapid HIV Test Garners Additional Tender Sales in China

Canada NewsWire   July 14, 2014
0 stars

MedMira Announces Chief Financial Officer Transition

Canada NewsWire   July 11, 2014
0 stars

MedMira Reports Third Quarter Results

Canada NewsWire   June 27, 2014
0 stars

Latest Bullboard Posts

  • RE:dear mr meile

    0 stars

    what's your point ??????????   ???????????????????

    3 stars


  • dear mr meile

    1 star

    i look forward to your call as per your emaill you sent to me doug

    2 stars


  • $ 192.00/ 3.2k

    1 star

    Some Ass at work again today!!!!!!!!!!!!!!!!!!!!!!!!!!

    2 stars


  • RE:AACC

    3 stars

    another opportunity. LETS SEE THE SALES !

    1.5 stars


  • AACC

    5 stars

    ends thursday. expect news by aug 6th. http://www.aacc.org/events/2014_annual_meeting/abstracts/Documents/AACC_14_AcceptedAbstractBook...

    2 stars